Niccoli Antonio A, Artesi Anna L, Candio Francesco, Ceccarelli Sara, Cozzali Rita, Ferraro Luigi, Fiumana Donatella, Mencacci Manuela, Morlupo Maurizio, Pazzelli Paola, Rossi Laura, Toscano Marco, Drago Lorenzo
*Hospital of Foligno and Spoleto, AUSL 2 Umbria ‡IRCCS Galeazzi Hospital Milan †Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
J Clin Gastroenterol. 2014 Nov-Dec;48 Suppl 1:S34-6. doi: 10.1097/MCG.0000000000000233.
The goal of this study was to evaluate the clinical efficacy of an intake of Lactobacillus salivarius LS01 (DSM 22775) for the treatment of atopic dermatitis (AD) in children.
AD is an inflammatory and pruritic chronic relapsing skin disorder with multifactorial etiopathology. Some evidence suggests that probiotics may improve AD by modulating the immune system and the composition of intestinal microbiota.
A total of 43 patients aged from 0 to 11 years were enrolled in the study (M/F ratio=1:1) and treated with the probiotic strain L. salivarius LS01. Clinical efficacy of probiotic treatment was assessed from baseline by changes in itch index and in the objective SCORAD/SCORAD index.
Patients being given probiotic treatment showed a significant improvement in clinical parameters (SCORAD and itch values) from baseline. The reduction in SCORAD and itch index observed after 4 weeks of treatment also persisted after the cessation of probiotic supplementation.
L. salivarius LS01 seems to be able to improve the quality of life of children affected by AD and, as a consequence, it may have promising clinical and research implications.
本研究的目的是评估摄入唾液乳杆菌LS01（DSM 22775）治疗儿童特应性皮炎（AD）的临床疗效。
AD是一种具有多因素病因病理的炎症性和瘙痒性慢性复发性皮肤病。一些证据表明，益生菌可能通过调节免疫系统和肠道微生物群的组成来改善AD。
共有43名年龄在0至11岁之间的患者纳入研究（男/女比例=1:1），并接受益生菌菌株唾液乳杆菌LS01治疗。从基线开始，通过瘙痒指数和客观SCORAD/SCORAD指数的变化评估益生菌治疗的临床疗效。
接受益生菌治疗的患者临床参数（SCORAD和瘙痒值）较基线有显著改善。治疗4周后观察到的SCORAD和瘙痒指数降低在停止补充益生菌后也持续存在。
唾液乳杆菌LS01似乎能够改善AD患儿的生活质量，因此，它可能具有广阔的临床和研究前景。
